All
Valeant outbids Merz for Obagi
April 8th 2013After Valeant Pharmaceuticals made a push to buy Obagi Medical Products for about $344 million in late March, Merz Pharma Group stepped up with an offer of about $384 million, but has since dropped its bid for the aesthetic skincare manufacturer, according to reports.
For some skin cancers, clinicians must consider less expensive options than Mohs surgery
April 1st 2013Although Mohs micrographic surgery represents the gold standard for treatment of many skin cancers, says an expert, healthcare reform dictates that dermatologists also consider less costly options when appropriate.
Staged excision techniques for lentigo maligna address challenges
April 1st 2013The many vagaries of lentigo maligna (LM) or melanoma in situ typically demand staged excision techniques for maximal margin control, according to an expert who spoke at the 71st annual American Academy of Dermatology conference.